Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
9 studies found for:    "celldex therapeutics" | Open Studies
Show Display Options
Rank Status Study
1 Available Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Condition: Recurrent GBM
Intervention: Biological: rindopepimut
2 Recruiting A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Clear-cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Kidney Diseases;   Kidney Neoplasms;   Metastatic Renal Cell Carcinoma
Intervention: Drug: CDX-014
3 Recruiting A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
Condition: Advanced Cancer
Intervention: Biological: CDX-0158 (formerly known as KTN-0158)
4 Recruiting A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Ovarian Carcinoma;   Colorectal Cancer (CRC);   Renal Cell Carcinoma (RCC) (Phase ll Only);   Glioblastoma (GBM) (Phase ll Only)
Intervention: Drug: Combination of varlilumab and nivolumab
5 Recruiting A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Condition: Melanoma
Interventions: Drug: glembatumumab vedotin;   Drug: glembatumumab vedotin and varlilumab;   Drug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
6 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions: Drug: CDX-011;   Drug: Capecitabine
7 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin
8 Recruiting FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: FLT3 Ligand Therapy (CDX-301);   Radiation: Stereotactic Body Radiotherapy (SBRT)
9 Recruiting Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Condition: Squamous Cell Carcinoma of the Lung
Interventions: Drug: Phase I: Glembatumumab Vedotin;   Drug: Phase II: Glembatumumab Vedotin

Study has passed its completion date and status has not been verified in more than two years.